#ESMO26 Can two ADCs + IO push response rates even higher in 1L metastatic urothelial cancer?
🚨TROPHY-U-01 Cohort 7, evaluating sacituzumab govitecan + enfortumab vedotin + zimberelimab (N=21).
🔹 ORR 81%, including 14% CR
🔹 Median DOR 16.7 months
🔹 Median PFS 19.3 months
🔹 Median OS not reached
🔹 Grade ≥3 treatment-related AEs: 52%; 33% discontinued ≥1 agent
Impressive early activity from dual ADC targeting Trop-2 + Nectin-4, but the key question is whether the added efficacy justifies the toxicity over EV+pembrolizumab.
@UroToday @myESMO
330 浏览 · 6 赞 · 3 转发 · 1 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org- Amy@AmyOtto8
@chavarriagaj Challenge is the high CR rate seen with EV +P in EV 302. It’s curious why we don’t see it here. And I like the dual payload approach
来源：Julian Chavarriaga · x.com